Combinatorial Cancer Immunotherapies
- 1 January 2016
- book chapter
- Published by Elsevier
- Vol. 130, 251-277
Abstract
No abstract availableKeywords
This publication has 163 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive MiceImmunity, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences, 2010
- A non‐redundant role for OX40 in the competitive fitness of Treg in response to IL‐2European Journal of Immunology, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006